Condition: Solid Tumor · Sponsor: Sanofi
This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generation aCTLA4 (ADG126) or with bevacizumab. 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable. Approximately 542 participants will be exposed to the study intervention: * approximately 123 participants in part 1, * up to 410 participants in expansion/dose optimization part (part 2) * and up to 9 participants in Japan cohort F.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Christiana Care Health System - Newark- Site Number : 8400011 | Newark, Delaware, United States | Recruiting |
| University of Iowa- Site Number : 8400014 | Iowa City, Iowa, United States | Recruiting |
| The University of Kansas Cancer Center - Westwood- Site Number : 8400008 | Westwood, Kansas, United States | Recruiting |
| Karmanos Cancer Institute - Detroit- Site Number : 8400006 | Detroit, Michigan, United States | Recruiting |
| John Theurer Cancer Center- Site Number : 8400001 | Hackensack, New Jersey, United States | Recruiting |
| NYU Langone Medical Center- Site Number : 8400013 | New York, New York, United States | Recruiting |
| Rhode Island Hospital - Providence - Eddy Street- Site Number : 8400004 | Providence, Rhode Island, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center- Site Number : 8400005 | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center- Site Number : 8400010 | Seattle, Washington, United States | Recruiting |
| Servicios Médicos URUMED SpA_Investigational Site Number : 1520002 | Rancagua, General Bernardo O'Higgins, Chile | Recruiting |
| BIOCINETIC Ltda_Investigational Site Number : 1520008 | Santiago, Reg Metropolitana de Santiago, Chile | Recruiting |
| Centro de Investigacion Clinica Bradford Hill_Investigational Site Number : 1520004 | Santiago, Reg Metropolitana de Santiago, Chile | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05584670